CDKL2: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: CDKL2

NCBI ID: G8999

CDKL2

CDKL2: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, leading to a range of symptoms such as memory loss, confusion, mood changes, and eventually, the loss of independence and death. Despite being a common age-related condition, the exact cause of Alzheimer's disease is not known, and current treatments are limited in their effectiveness. Therefore, identifying potential drug targets and biomarkers is crucial for developing new, more effective therapies.

CDKL2: A Potential Drug Target

CDKL2 (CDKL2-HUMAN) is a protein that is expressed in the brain and has been implicated in the development and progression of Alzheimer's disease. Its full name is casein kinase 2-related protein, and it is a key regulator of the intracellular signaling pathway known as the TGF-β pathway. The TGF-β pathway plays a crucial role in the development and maintenance of brain cells, and alterations in its activity have been implicated in a wide range of neurodegenerative diseases, including Alzheimer's disease.

Studies have shown that CDKL2 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in the brains of individuals with the disease. Additionally, overexpression of CDKL2 has been shown to increase the risk of developing Alzheimer's disease in animal models of the disease. These findings suggest that CDKL2 may be a potential drug target for Alzheimer's disease.

CDKL2 as a Biomarker

One of the challenges in the development of new treatments for Alzheimer's disease is the lack of objective biomarkers that can be used to measure the progression of the disease and the effectiveness of new treatments. CDKL2 may provide such a biomarker, as its levels can be easily measured and its expression is often reduced in the brains of individuals with Alzheimer's disease.

Studies have shown that the levels of CDKL2 are reduced in the brains of individuals with Alzheimer's disease, and that overexpression of CDKL2 has been shown to increase the risk of developing the disease. Additionally, some studies have shown that CDKL2 may be a useful biomarker for tracking the progression of the disease, as its levels can be used to predict the outcome of new treatments.

Conclusion

In conclusion, CDKL2 is a protein that has been implicated in the development and progression of Alzheimer's disease. Its expression is reduced in the brains of individuals with the disease and its overexpression has been shown to increase the risk of developing the disease. Additionally, studies have shown that CDKL2 may be a potential drug target for Alzheimer's disease and a useful biomarker for tracking the progression of the disease. Further research is needed to determine the effectiveness of CDKL2 as a potential drug target and biomarker for Alzheimer's disease.

Protein Name: Cyclin Dependent Kinase Like 2

The "CDKL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets